News, Scientific publications and Events

Allergology / ent Scientific Publication RHINOSECTAN®

New scientific publication on RHINOSECTAN®

A new publication carried out in a nasal mucosa model demonstrates the barrier effect of Rhinosectan®, which confirms its utility in nasal respiratory diseases such as allergic rhinitis. Rhinosectan® is a Class I medical device and complies with the Essential Requirements of Directive 93/42/EEC and subsequent amendments. (CE, Noventure SL) De Servi B et al. Protective barrier properties of Rhinosectan® spray (containing xyloglucan) on an organotypic 3D airway tissue model (MucilAir): results of an in vitro study. Allergy Asthma Clin Immunol. 2017 Aug 10;13:37

Gastroenterology News XILAPLUS®

New partnership: Xilaplus® AF in Turkey

Noventure is delighted to announce its new partnership with Generica İlaç to market Noventure’s Xilaplus® AF in Turkey.

Gastroenterology News GELSECTAN®

Congresses: Noventure participates at NeuroGASTRO 2017, Cork, Ireland, with an innovative approach to IBS

Noventure, as part of its continued commitment to Gastroenterology, participated at the recent NeuroGASTRO 2017 meeting, which brought together leading experts and young investigators in neurogastroenterology, digestive motility and functional gastrointestinal diseases from Europe and from all around the world. The new product Gelsectan® was depicted at the Noventure´s stand as a teaser campaign, under the motto “Mucoprotection”.